Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Large Prostate Cancer Prevention Trial Opens

By HospiMedica staff writers
Posted on 30 Jul 2001
A new study of 32,400 men at more than 400 sites over 12 years will seek to determine if two dietary supplements, selenium and vitamin E, can protect against prostate cancer, the most common form of cancer, after skin cancer, in men. More...
Called SELECT, the trial was launched by the U.S. National Cancer Institute (NCI) and a network of researchers known as the Southwest Oncology Group (SWOG).

Selenium and vitamin E, both naturally occurring nutrients, are antioxidants. They are capable of neutralizing toxins known as free radicals that might otherwise damage the genetic material of cells and possibly lead to cancer. The nutrients were chosen for this study because of the favorable results of two other large cancer prevention trials. In a study of selenium to prevent nonmelanoma skin cancer, investigators found that while the supplement did not reduce skin cancer, it decreased the incidence of prostate cancer in men by more than 60%. Another trial, in which beta carotene and vitamin E were tested to prevent lung cancer, showed that men who took vitamin E had 32% less prostate cancer.

"SELECT is the critical next step for pursuing the promising leads we saw for prevention of prostate cancer,” said Leslie Ford, M.D., associate director for clinical research in NCI's Division of Cancer Prevention. "The only way to determine the real value of these supplements for prostate cancer is to do a large clinical trial focused specifically on this disease.”




Related Links:
Southwest Oncology Group
National Cancer Institute

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Hemostatic Agent
HEMOBLAST Bellows
VTE Prevention System
Flowtron ACS900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The 3D-printed microneedle patch boosts live-virus vaccine delivery (Photo courtesy of IIS/University of Tokyo)

3D-Printed Delivery System Enhances Vaccine Delivery Via Microneedle Array Patch

The COVID-19 pandemic underscored the need for efficient, durable, and widely accessible vaccines. Conventional vaccination requires trained personnel and cold-chain logistics, which can slow mass immunization... Read more

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.